Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy

C. Lefebvre, E. Martin, L. E. L. Hendriks, R. Veillon, F. Puisset, L. Mezquita, R. Ferrara, M. Sabatier, T. Filleron, A-M C. Dingemans, B. Besse, C. Raherisson, J. Mazieres*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

37 Downloads (Pure)
Original languageEnglish
Article number100788
Number of pages7
JournalRespiratory medicine and research
Volume78
DOIs
Publication statusPublished - Nov 2020

Keywords

  • DOCETAXEL
  • NIVOLUMAB
  • PHASE-3

Cite this